# BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma

> **NCT04072042** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Apatinib monotherapy

## Key facts

- **NCT ID:** NCT04072042
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-10-30
- **Primary completion:** 2026-10-30
- **Final completion:** 2027-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072042, "BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04072042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*